Willingdon Wealth Management grew its position in CVS Health Corp (NYSE:CVS) by 4.0% during the third quarter, HoldingsChannel reports. The institutional investor owned 43,029 shares of the pharmacy operator’s stock after acquiring an additional 1,647 shares during the quarter. Willingdon Wealth Management’s holdings in CVS Health were worth $3,387,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in CVS. Camarda Financial Advisors LLC acquired a new stake in CVS Health in the 2nd quarter worth approximately $102,000. Kiley Juergens Wealth Management LLC acquired a new stake in CVS Health in the 2nd quarter worth approximately $103,000. Legacy Advisors LLC boosted its stake in CVS Health by 7,100.0% in the 2nd quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock worth $116,000 after purchasing an additional 1,775 shares in the last quarter. Squar Milner Financial Services LLC acquired a new stake in CVS Health in the 2nd quarter worth approximately $122,000. Finally, Canton Hathaway LLC acquired a new stake in CVS Health in the 3rd quarter worth approximately $126,000. Institutional investors and hedge funds own 82.42% of the company’s stock.
In other CVS Health news, EVP Eva C. Boratto sold 13,311 shares of the firm’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the completion of the transaction, the executive vice president now directly owns 55,162 shares of the company’s stock, valued at approximately $4,256,299.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Lisa Bisaccia sold 21,534 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $80.00, for a total transaction of $1,722,720.00. The disclosure for this sale can be found here. Insiders have sold a total of 43,409 shares of company stock valued at $3,392,097 over the last three months. 0.53% of the stock is currently owned by insiders.
CVS opened at $79.83 on Friday. CVS Health Corp has a 12-month low of $60.14 and a 12-month high of $83.88. The company has a quick ratio of 1.87, a current ratio of 2.44 and a debt-to-equity ratio of 1.66. The company has a market cap of $80.25 billion, a price-to-earnings ratio of 13.53, a price-to-earnings-growth ratio of 1.05 and a beta of 0.98.
CVS Health (NYSE:CVS) last posted its quarterly earnings results on Tuesday, November 6th. The pharmacy operator reported $1.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.71 by $0.02. CVS Health had a net margin of 1.65% and a return on equity of 18.69%. The company had revenue of $47.27 billion during the quarter, compared to analyst estimates of $47.22 billion. During the same period last year, the firm posted $1.50 EPS. CVS Health’s revenue for the quarter was up 2.4% compared to the same quarter last year. Analysts expect that CVS Health Corp will post 7.04 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Wednesday, October 24th were given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 2.51%. The ex-dividend date of this dividend was Tuesday, October 23rd. CVS Health’s dividend payout ratio is presently 33.90%.
A number of research firms recently commented on CVS. ValuEngine upgraded shares of CVS Health from a “sell” rating to a “hold” rating in a research note on Tuesday. Loop Capital set a $80.00 target price on shares of CVS Health and gave the stock a “hold” rating in a research note on Friday. Royal Bank of Canada set a $100.00 target price on shares of CVS Health and gave the stock a “buy” rating in a research note on Wednesday. Morgan Stanley set a $100.00 target price on shares of CVS Health and gave the stock a “buy” rating in a research note on Wednesday. Finally, Wolfe Research began coverage on shares of CVS Health in a research note on Thursday, October 25th. They issued a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $89.38.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Read More: Price to Earnings Ratio (PE)
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.